Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.91 -0.14 (-0.27%)

Streaming Delayed Price Updated: 11:27 AM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

45 46 Next >

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines ↗

January 06, 2023

CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.

Via InvestorPlace

The Year of the Tripledemic

January 03, 2023

COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which...

Via TheNewswire.com

Topics Death

The Year of the Tripledemic

January 03, 2023

The Year of the Tripledemic

Via News Direct

Topics Death

GSK's Debt Overview ↗

December 06, 2022

Over the past three months, shares of GSK Inc. (NYSE:GSK) moved higher by 19.05%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...

Via Benzinga

What You Missed On Wall Street On Friday ↗

December 31, 2022

In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.

Via Talk Markets

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗

December 30, 2022

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

Via Benzinga

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

2 Smartest Tech Stocks to Buy in 2022 and Beyond ↗

December 20, 2022

The tech space is still bursting with opportunities for long-term investors.

Via The Motley Fool

Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says ↗

December 14, 2022

Via Benzinga

Options Trader Betting On GSK Stock Rising Heading Into 2023 ↗

December 13, 2022

Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK).

Via Benzinga

Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders ↗

December 13, 2022

Via Benzinga

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

December 13, 2022

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

December 11, 2022

From GSK plc

Via Business Wire

Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

December 09, 2022

Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.

Via MarketBeat

France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine ↗

December 08, 2022

Via Benzinga

GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial ↗

December 07, 2022

Via Benzinga

Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07 ↗

December 07, 2022

Benzinga

Via Benzinga

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac ↗

December 07, 2022

Via Benzinga

These 3 Stocks Escaped Tuesday's Market Downdraft ↗

December 06, 2022

Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.

Via The Motley Fool

Why GSK Plc And Sanofi SA Stock Are Shooting Higher ↗

December 06, 2022

Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.

Via Benzinga

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

November 30, 2022

Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment

Via MarketBeat

Topics Intellectual Property

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains ↗

November 25, 2022

Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.

Via Benzinga

After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US ↗

November 22, 2022

Via Benzinga

Dividend Income Update October 2022 ↗

November 17, 2022

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio.

Via Talk Markets

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Peering Into GSK's Recent Short Interest ↗

November 15, 2022

GSK's (NYSE:GSK) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.7% of all regular shares that are...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.